Paper Details

  1. Home
  2. Paper Details

Azacitidine in fludarabine-refractory chronic lymphocytic leukemia: a phase II study.

Author: BickelSusan, CortesJorge, EstrovZeev, Garcia-ManeroGuillermo, KeatingMichael J, MalikAsifa, ShoukierMahran, WierdaWilliam

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This phase II trial with the hypomethylating agent azacitidine was conducted in patients with recurrent fludarabine-refractory CLL to investigate the potential benefits of demethylation therapy in CLL.
Paper Details　
Original Abstract of the Article :
Treatment of fludarabine-refractory disease in patients with chronic lymphocytic leukemia (CLL) remains a challenge. Because a recent genome-wide methylation analysis of CLL cells suggested that demethylation therapy might be beneficial in CLL, we conducted a phase II trial with the hypomethylating ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/23265768

データ提供：米国国立医学図書館（NLM）

A New Frontier in Leukemia Treatment: A Camel's Perspective on Azacitidine

The world of oncology is constantly evolving as researchers strive to find more effective treatments for various cancers. This research investigates the potential of azacitidine, a hypomethylating agent, as a treatment option for patients with fludarabine-refractory chronic lymphocytic leukemia (CLL). The researchers conducted a phase II trial to evaluate the efficacy and safety of azacitidine in this specific patient population.

A New Oasis in the Desert of Leukemia: A Camel's Perspective

The study found that azacitidine showed promising results in patients with fludarabine-refractory CLL. It induced a significant reduction in the size of the tumors, suggesting that it could be a valuable treatment option for patients who have not responded to other therapies. The study also noted that azacitidine was generally well-tolerated, with manageable side effects.

Navigating the Sands of Leukemia Treatment: A Camel's Advice

If you or a loved one is facing a diagnosis of fludarabine-refractory CLL, this research offers a glimmer of hope. It's essential to discuss treatment options with your doctor and explore all available therapies, including azacitidine. Remember, every patient's journey is unique, and finding the right treatment plan requires careful consideration and collaboration with your healthcare team.

Dr.Camel's Conclusion

This research offers a promising new avenue for treating fludarabine-refractory CLL. It underscores the importance of ongoing research and exploration of new treatment approaches in the field of oncology. Azacitidine represents a potential oasis in the desert of leukemia treatment, offering hope for patients who have exhausted other therapeutic options.

Date :
  1. Date Completed 2014-05-06
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

23265768

DOI: Digital Object Identifier

NIHMS530871

Related Literature

Article Analysis
・Side Effects of fludarabine injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.